Immunotherapy vs. chemotherapy in subsequent treatment of malignant pleural mesothelioma: which is better?

HIGHLIGHTS

• who: Xiaotong Guo et al. from the Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China have published the paper: Immunotherapy vs. Chemotherapy in Subsequent Treatment of Malignant Pleural Mesothelioma: Which Is Better?, in the Journal: (JOURNAL) of 28/02/2023
• what: The authors aimed to compare the efficacy of targeting drugs and immune-checkpoint inhibitors (ICIs) as subsequent therapy for relapsed MPM. Finally,Finally, 43 articles were selected for the teria forstudy, this study, the authors assessed carefully for eligibility. To conclude, this study demonstrated that ICIs might not be superior to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.